Drug-Target Binding Mode Determination
Through high-resolution protein structure determination, we can identify and characterize binding pockets for compound development targeting disease-causing proteins. The structural information of compound-protein complexes can then be utilized for drug validation and iterative optimization in the development pipeline
Multi-Subunit Complex Structure Determination
Through high-resolution structural determination of multi-subunit protein complexes, we can analyze mechanisms of action (MOA) and protein-protein interactions for various applications.
Antibody-Antigen Binding Structure Determination
We provide a high-resolution structural determination platform for therapeutic antibody development that utilizes epitope and paratope mapping of antigen-antibody complexes to characterize binding structural properties and guide antibody design and optimization of binding efficiency for novel antigens. Through high-throughput screening approaches, we can rapidly assess the binding characteristics of large numbers of candidate antibodies.
Ion Channel Structure Determination
Membrane proteins represent a significant portion of drug development targets, comprising approximately 70% of currently approved therapeutics, with ion channels and GPCRs accounting for 50% of small-molecule drug targets. We have established high-resolution (2.28Å~3.0Å) cryo-EM structural determination capabilities and expertise across diverse ion channels, including voltage-gated Cl⁻ channels, Ca²⁺-gated Cl⁻ channels, K⁺ channels, and H⁺ channels.
Small Protein Structure Determination
Our platform specializes in elucidating the structure and function of low molecular weight proteins that serve critical roles in disease pathology. We can achieve high-resolution structural determination of proteins under 50kDa through advanced optimization techniques, overcoming the limitations of conventional cryo-EM analysis methods.